Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a single antibiotic dose after sex stop STIs?

NCT ID NCT07397403

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether taking a single 200 mg dose of doxycycline within 24–72 hours after unprotected sex can prevent gonorrhea, chlamydia, and syphilis in men who have sex with men. Researchers in Bangkok will enroll 400 participants and follow them for 12 weeks. If effective, this could offer a new prevention tool for high-risk individuals.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
doxycycline
What this could lead to
If it works, this could provide a simple, on-demand pill to reduce the risk of common sexually transmitted infections in high-risk groups.
What could go wrong
This is a single-site trial in Thailand, so results may not apply elsewhere. Doxycycline may not prevent all STIs, and overuse could lead to antibiotic resistance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 days

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Biological male, aged not over 60 years Thai nationality Able to read, communicate, and understand the Thai language Men who have sex with men (MSM), aged 18 years or older and not over 60 years Having at least one of the following risk factors: A history of condomless sex, or condom failure (breakage, leakage, or slippage), via any sexual route with at least two sexual partners within the past 3 months A diagnosis of gonorrhea, chlamydia, or syphilis within the past 6 months Current use of HIV pre-exposure prophylaxis (PrEP) Willing and able to participate in study procedures (e.g., able to return to the clinic for scheduled testing for gonorrhea, chlamydia, and syphilis; able to complete doxycycline use records; and able to receive follow-up phone calls from the research team) Willing and able to provide written informed consent to participate in the study \- Exclusion Criteria: * History of allergy to tetracycline-class antibiotics Diagnosed with syphilis and not yet treated, or currently receiving treatment with benzathine penicillin G or doxycycline Receipt of benzathine penicillin G within the past 12 weeks Prior receipt of a gonorrhea vaccine Current use of medications or products that may interact with doxycycline, including: Vitamin A derivatives (e.g., isotretinoin, acitretin) Antiepileptic drugs (e.g., phenytoin, carbamazepine, phenobarbital) Immunosuppressive agents (e.g., methotrexate) Medications for heart failure or cardiac arrhythmias (e.g., digoxin) Anticoagulants (e.g., warfarin) Use of oral or injectable medications that affect blood cells, such as anticancer drugs, chemotherapy, systemic corticosteroids, or targeted therapies History of renal impairment (eGFR \< 60 mL/min/1.73 m²) or hepatic impairment (AST or ALT \> 3 times the upper limit of normal) Uncontrolled or unstable underlying diseases, such as hematologic disorders, cancer, autoimmune diseases, or neurological disorders Severe medical or psychiatric conditions that, in the investigator's judgment, may increase study-related risk or impair the participant's ability to provide informed consent Alcohol dependence (inability to control alcohol consumption, withdrawal symptoms upon reduction or cessation, or continued use despite harm) or illicit drug dependence (regular, uncontrolled use) within the past 12 months prior to enrollment, which may affect doxycycline use for STI prevention Previous participation in this study with prior randomization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chlamydia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bangrak STIs Center

    RECRUITING

    Sathorn, Bangkok, 10120, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.